Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Previously Treated Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma

NCT06178588 is registered in ClinicalTrials.gov with University of Kansas Medical Center as lead sponsor.

NCT NCT06178588
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06178588 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Previously Treated Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma
Lead sponsor
University of Kansas Medical Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 1, 2024
Completion date
November 1, 2026
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced cholangiocarcinoma, metastatic cholangiocarcinoma, recurrent cholangiocarcinoma, stage iii hilar cholangiocarcinoma ajcc v8, stage iii intrahepatic cholangiocarcinoma ajcc v8, stage iv hilar cholangiocarcinoma ajcc v8, stage iv intrahepatic cholangiocarcinoma ajcc v8